Recently, we have shown that the KRAS-variant, and other novel inherited mutations like it, appear to predict altered immunity, and possibly autoimmunity.
Our findings with the KRAS-variant led us to investigate a large panel of genetic biomarkers like the KRAS-variant, which also disrupt microRNA signaling. We have now found that these biomarkers also predict altered immunity, as presented at American Society of Clinical Oncology (ASCO 2017).
The MiraKind community brings together individuals with the KRAS-variant to share their stories, learn from one other, and offer support. Learn more.
Spread the Word!
We need your help to let people know about the KRAS-variant. Hover over an image to share.
Or click a button below:
- Weidhaas, J.B., J. Harris, D. Schaue, A. Chen, R. Chin, R. Axelrod, A.K. El-Naggar, A.K. Singh, T.J. Galloway, D. Raben, D. Wang, C. Matthiesen, V. Avizonis, R.R. Manon, O. Yumen, P.F. Nguyen-Tan, A. Trotti, H. Skinner, Q. Zhang, R.L. Ferris, D. Sidransky, and C.H. Chung, The KRAS-variant and Cetuximab Response in Head and Neck Squamous Cell Cancer, A Secondary Analysis of a Randomized Cinical Trial. JAMA Oncology, 2017. 3(4): p. 483-491